MEDNAX (NYSE: MD) is expected to report Q3 earnings on Nov. 1. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict MEDNAX's revenues will grow 15.3% and EPS will grow 6.7%.

The average estimate for revenue is $469.9 million. On the bottom line, the average EPS estimate is $1.27.

Revenue details
 Last quarter, MEDNAX logged revenue of $449.5 million. GAAP reported sales were 14% higher than the prior-year quarter's $393.4 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, EPS came in at $1.22. GAAP EPS of $1.22 for Q2 were 6.1% higher than the prior-year quarter's $1.15 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 34.6%, 150 basis points worse than the prior-year quarter. Operating margin was 22.2%, 150 basis points worse than the prior-year quarter. Net margin was 13.5%, 70 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $1.82 billion. The average EPS estimate is $4.77.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 177 members out of 183 rating the stock outperform, and six members rating it underperform. Among 58 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 56 give MEDNAX a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MEDNAX is outperform, with an average price target of $76.54.